Abstract
The development of intellectual property rights for biotechnology has occurred in a series of complex and often contentious steps. By granting many of the first patents for genetically engineered organisms and biological molecules, the US has played a leading role in shaping policy worldwide. This article reviews the role of patents in the development of biotechnology and discusses the new challenges posed by the integration of genomics into the drug discovery process.